Shares of Advaxis, Inc. (ADXS) are higher by 5.72% to $14.01 in late morning trading on Tuesday following positive KEYTRUDA data from Merck (MRK).
Merck this morning announced that the pivotal Phase 3 study (KEYNOTE-006) investigating KEYTRUDA (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the study’s independent Data Monitoring Committee.
Advaxis in January said it anticipates commencing with Merck patient enrollment for the Phase 1/2 ADXS-PSA/KEYTRUDA (pembrolizumab) combination study in metastatic, castration-resistant prostate cancer (mCRPC) in first quarter 2015.
During today’s trading session, ADXS printed higher highs for the majority of the morning, before settling into an intraday range of $13.99 to $14.10 with its 52-week range being $2.46 to $14.50.
Fundamentally, ADXS shows the following financial data:
- $30.58 million in cash in most recent quarter
- $23.38 million t-12 total assets
- $20.63 million total equity
- $1,000.00K t-12 revenue
- ($16.53) million annual net income
- ($17.05) million free cash flow
On valuation measures, Advaxis Inc. shares have a T-12 price/sales ratio of 361.32 and a price/book for the same period of 10.16. EPS is ($0.94). The name has a market cap of $383.10 million and a median Wall Street price target of $14.00 with a high target of $15.00. Currently there are 3 analysts that rate ADXS a ‘Buy’. No analyst rates it a ‘Hold’ or a ‘Sell’.
In terms of share statistics, Advaxis Inc. has a total of 23.65 million shares outstanding with 9.11% held by insiders and 9.60% held by institutions. The stock’s short interest currently stands at 9.90%, bringing the total number of shares sold short to 2.15 million.
Shares of the Princeton New Jersey-based company are up 170.47% year-over-year and 65.79% year-to-date.
Leave a Reply